Krystal Biotech, Inc. KRYS Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number

Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number at other companies

Merck & Co.MRK

——

ViatrisVTRS

——

Other financials

Income statement

See full

Revenue$116.4M+31.9%

Operating income$53.7M+48.1%

Net income$55.9M+56.5%

EPS (diluted)$1.83+52.5%

Balance sheet

See full

Cash & equivalents$501.3M+62.4%

Total debt$9.1M-5.7%

Total equity$1.3B+29.7%

Total assets$1.4B+30.0%

Cash flow

See full

Operating cash flow$80.4M+160%

CapEx$7.1M+15.2%

Free cash flow$73.2M+196%

Valuation

See full

Market cap$10.26B+45.4%

Enterprise value$9.77B+44.2%

P/E45.6×-11.3×

P/S24.6×+3.4×

Profitability

See full

Operating margin42.8%+10.2pp

Net margin53.9%+16.7pp

FCF margin56.9%+16.5pp

Returns & leverage

See full

Return on equity19.9%+6.0pp

Debt / equity0×0.0×

Current ratio9.5×-0.2×

Where this comes from

Reported directly by Krystal Biotech, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber.

The official record: Krystal Biotech, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Krystal Biotech, Inc.'s share based compensation arrangement by share based payment award options exercisable number.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Krystal Biotech, Inc.'s share based compensation arrangement by share based payment award options exercisable number?: Krystal Biotech, Inc. (KRYS) reported share based compensation arrangement by share based payment award options exercisable number of $1.27M in Q1 2026.
How has Krystal Biotech, Inc.'s share based compensation arrangement by share based payment award options exercisable number changed year-over-year?: Krystal Biotech, Inc.'s share based compensation arrangement by share based payment award options exercisable number increased by 8.6% year-over-year, from $1.17M to $1.27M.